Page 1

Exhibit 99.1 S + SimulationsPlus Cognigen DILIsym Services Lixoft For Further Information : Simulations Plus , Inc. 42505 10th Street West Lancaster , CA 93534-7059 CONTACT : Simulations Plus Investor Relations Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com For Immediate Release : July 12 , 2021 Hayden IR Mr. Brian Siegel 346-396-8696 brian@haydenir.com Simulations Plus Reports Third Quarter Fiscal 2021 Financial Results Third quarter total revenue increased 4 % to $ 12.8 million , with software revenue up 21 % ; Board of Directors announces quarterly dividend of $ 0.06 per share LANCASTER , CA , July 12 , 2021 - Simulations Plus , Inc. ( Nasdaq : SLP ) , a leading provider of modeling and simulation solutions for the pharmaceutical , biotechnology , chemical , and consumer goods industries , today reported financial results for its third quarter of fiscal 2021 , ended May 31 , 2021 . Third Quarter Fiscal 2021 Financial highlights ( compared with the corresponding period last fiscal year ) : Total revenue increased 4 % to $ 12.8 million ; Software revenue increased 21 % to $ 8.3 million ; Services revenue declined 18 % to $ 4.5 million ; Gross profit increased 7 % to $ 10.3 million ; Gross margin increased from 78 % to 81 % ; Net income increased 29 % to $ 3.8 million ; Diluted earnings per share increased 13 % to $ 0.18 per share . YTD Financial highlights ( compared with the corresponding period last fiscal year ) : Total revenue increased 14 % to $ 36.6 million ; Software revenue increased 32 % to $ 22.3 million ; Services revenue declined 6 % to $ 14.3 million ; Gross profit increased 20 % to $ 28.8 million ; Gross margin increased from 75 % to 79 % ; Net income increased 33 % to $ 9.5 million ; Diluted earnings per share increased 18 % to $ 0.46 per share . Shawn O'Connor , chief executive officer of Simulations Plus , said : " Our software business continued its strong performance during the quarter , with revenues increasing by 21 % versus last year as product updates and cross - selling initiatives led to an acceleration in growth rates . However , our overall growth rate was moderated due to a higher than normal number of late quarter project delays and drug development program cancellations in our services business , which has historically had periods of volatility . Despite these delays and cancellations , our services pipeline continued to expand , and backlog grew in the quarter . While these trends are encouraging and support our long - term outlook , the delays in services projects will impact the growth rates for the remainder of our fiscal year , and we now expect full - year revenue growth of 5 to 10 % . " 1